Results 41 to 50 of about 562,472 (163)

The sodium in sodium oxybate: is there cause for concern? [PDF]

open access: yes, 2020
Sodium oxybate (SO), the sodium salt of γ-hydroxybutyric acid, is one of the primary pharmacologic agents used to treat excessive sleepiness, disturbed nighttime sleep, and cataplexy in narcolepsy. The sodium content of SO ranges from 550 to 1640 mg&
Kushida, Clete A, Avidan, Alon Y
core   +1 more source

Narcolepsy and rapid eye movement sleep

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini   +4 more
wiley   +1 more source

Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation

open access: yes, 2018
Background: Narcolepsy is a lifelong neurological disorder with onset commonly in childhood or adolescence. No drugs are indicated for cataplexy and excessive daytime sleepiness in paediatric patients with narcolepsy.
Ruoff, Chad   +20 more
core   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates

open access: yesSleep Medicine: X
Objective/Background: Preference for extended-release, once-nightly sodium oxybate (ON-SXB, FT218) vs twice-nightly immediate-release (IR) oxybate was assessed in participants switching from IR oxybate to ON-SXB in an open-label/switch study, RESTORE ...
Asim Roy   +14 more
doaj   +1 more source

Diagnostic Value of Psychomotor Vigilance Task for Severe Sleep Inertia in Idiopathic Hypersomnia Versus Other Sleep Disorders Without Sleep Inertia

open access: yesJournal of Sleep Research, EarlyView.
Diagnostic Value of PVT for Severe Sleep Inertia in Idiopathic Hypersomnia. ABSTRACT Sleep inertia impairs performance upon awakening and may be assessed using the psychomotor vigilance task (PVT). This study aimed to determine optimal PVT lapse cut‐offs at awakening to objectively measure sleep inertia by comparing patients with idiopathic hypersomnia
Elisa Evangelista   +6 more
wiley   +1 more source

Sodium Oxybate Alters Sleep Architecture and Reduces Emotional Selectivity in Memory‐Related Responses

open access: yesJournal of Sleep Research, EarlyView.
ABSTRACT Sleep supports memory consolidation. Non‐rapid eye movement (NREM) and rapid eye movement (REM) sleep have been proposed to support, respectively, declarative memory consolidation and the integration of the memory affective dimension. Here, we used sodium oxybate (SXB) to modify the NREM/REM proportion during one sleep night and assessed ...
Laure Colin   +7 more
wiley   +1 more source

Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence

open access: yes, 2017
Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults.
Pichini, Simona   +13 more
core   +1 more source

Postmortem Evidence of CRH Neuron Reduction in Narcolepsy Without Cataplexy With Borderline Hypocretin‐1 Levels

open access: yesJournal of Sleep Research, EarlyView.
ABSTRACT Narcolepsy is classified as type 1 (NT1) or type 2 (NT2) mainly according to hypocretin deficiency rather than cataplexy. While CRH neuron loss in the PVN has been described in NT1, it remains unclear whether similar changes occur in narcolepsy without cataplexy.
Ling Shan   +5 more
wiley   +1 more source

Risk of Hypertension and Mortality Among People With Narcolepsy or Idiopathic Hypersomnia: A Retrospective Cohort Analysis of the Danish National Patient Registry

open access: yesJournal of Sleep Research, EarlyView.
This retrospective cohort study using data from the Danish National Patient Registry shows that individuals with narcolepsy or idiopathic hypersomnia have greater prevalence and risk of incident hypertension compared with matched controls, highlighting the elevated cardiovascular risk associated with these conditions.
Poul Jørgen Jennum   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy